Adavosertib + Paclitaxel + Carboplatin + Gemcitabine + PLD
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
Conditions
Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
Trial Timeline
Jan 30, 2015 → Mar 8, 2023
NCT ID
NCT02272790About Adavosertib + Paclitaxel + Carboplatin + Gemcitabine + PLD
Adavosertib + Paclitaxel + Carboplatin + Gemcitabine + PLD is a phase 2 stage product being developed by AstraZeneca for Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation. The current trial status is completed. This product is registered under clinical trial identifier NCT02272790. Target conditions include Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02272790 | Phase 2 | Completed |
Competing Products
20 competing products in Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation